Search Results

You are looking at 1 - 10 of 10 items for :

  • Dermatological and Veneral Diseases x
Clear All
Open access

Željko P. Mijušković

;26:717-9. 78. Lacour JP. Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms. Br J Dermatol 2002;146(Suppl 61):17-9. 79. Owens DM, Watt FM. Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer 2003;3:444-51. 80. Miller SJ, Sun TT, Lavker RM. Hair follicles, stem cells and skin cancer. J Invest Dermatol 1993;100:288S-94S. 81. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science 2004

Open access

Hiva Fassihi, Kamran Iqbal, Trish Garibaldinos, Robert Sarkany, Julia Scarisbrick and Ljubomir Novaković

Abstract

Chronic graft-versus-host disease (GVHD) is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Approximately 10% of patients with GVHD develop sclerodermatous changes, which can cause significant morbidity and are often refractory to standard systemic immunosuppression. We present two cases of sclerodermatous GVHD. The first is a 39-year-old man, who had a matched sibling, undergoing allogeneic HSCT for severe aplastic anemia. The second patient is a 7-year-old boy, who had an allogeneic HSCT from his HLA-identical mother for acute myeloid leukemia (AML). Both patients presented with widespread sclerotic changes, resulting in joint contractures and significant functional difficulties. Studies have shown UVA1 phototherapy to be a promising and well tolerated treatment modality in patients with sclerotic skin diseases. Both of our patients were treated with UVA1, which resulted in a significant skin softening, improvement in joint mobility and quality of life. UVA1 appears to be an effective treatment for refractory sclerodermatous GVHD; however, long-term clinical studies in larger groups are needed to accurately evaluate its efficacy and safety.

Open access

Predrag Štilet and Miloš D. Pavlović

angiogenesis by disrupting endothelial cell migration and tube formation. J Exp Ther Oncol 2008;7:173-82. 16. Hasegawa K, Namekawa SH, Saga Y. MEK/ERK signaling directly and indirectly contributes to the cyclical self-renewal of spermatogonial stem cells. Stem Cells 2013;31:2517-27.

Open access

Tatjana Roš, Branislava Gajić, Milana Ivkov-Simić and Zorica Gajinov

Abstract

Basal cell carcinoma is a slow-growing, malignant epidermal tumor predominantly affecting sun exposed areas in Caucasians, accounting for up to 80% of all diagnosed skin cancers, with a rising incidence. Chronic UV radiation, in association with constitutional factors, plays the main role in its etiology. Inappropriate activation of the hedgehog signaling pathway seems to be a key pathogenesis mechanism. Basal cell carcinoma metastases are extremely rare, but it is a locally invasive tumor that can cause significant destruction of the surrounding tissues, with their functional and esthetic impairment. There are four main clinical types of basal cell carcinoma, although clinical classification is of poor prognostic significance. Preselection of suspicious lesions and treatment planning include noninvasive diagnostic techniques: dermoscopy, confocal microscopy and ultrasoud imaging, yet histopathology remains the “gold standard” of basal cell carcinoma diagnosis. In terms of the histological growth pattern, which is essential for the prognosis, basal cell carcinoma may be divided into circumscribed or diffuse types. Surgical excision is considered to be a first line treatment option, but there are numerous less invasive treatment modalities for low-risk basal cell carcinoma. Prevention strategies are focused on behavioral modifications, regular follow up and use of chemopreventive agents in high-risk patients.

Open access

Slobodan Stojanović, Marina Jovanović and Nada Vučković

;204(1):4–7. 7. Racette AJ, Adams AD, Kessler SE. Simultaneous lichen striatus in siblings along the same Blaschko line. Pediatr Dermatol 2009;26(1):50-4. 8. Verma P, Singal A, Yadav P, Sharma R. Concurrence of lichen striatus and localised pityriasis rosea: cutaneous mosaicism. Australas J Dermatol 2013;54(1):41-2. 9. Mun JH, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS. Lichen striatus occurring after allogenic peripheral blood stem cell transplantation in an adult with aplastic anemia. Ann Dermatol 2012;24(1):87-9. 10. Zhang Y, McNutt NS. Lichen striatus

Open access

Svetlana Popadić, Mirjana Gajić-Veljić, Biljana Marenović and Miloš Nikolić

;91(5):558–62. 3. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. Ann Allergy. 1994;73(3):197–202. 4. Castells M, Metcalfe DD, Escribano L. Diagnosis andtreatment of cutaneous mastocytosis in children:practical recommendations. Am J Clin Dermatol.2011;12(4):259-70. 5. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosisand treatment. Ann Hematol. 2002;81(12):677–90. 6. Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis a disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2008;105(40):686–92. 7

Open access

Kristina Semkova, Sonya Marina and Jana Kazandjieva

;102:2012-5. 29. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005;52:281-6. 30. Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed 2010;8:9-11. 31. Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010;13:327-35. 32. Greenberger S

Open access

Danijela Popović, Mirjana Paravina, Dragan Jovanović, Vesna Karanikolić and Dragana Ljubisavljević

Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009;54(2):193-5. 20. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2006;107(2):463–6. 21. Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 2013;13:72.

Open access

Jagoda Balaban, Dragana Popović and Svetlana Pavlović

and management of individuals with neurofibromatosis 1. J Med Genet 2007;44(2):81–8. 11. Gabriele AL, Ruggieri M, Patitucci A, Magariello A, Conforti FL, Mazzei R, et al. A novel NF1 gene mutation in an Italian family with neurofibromatosis type 1. Childs Nerv Syst 2011;27(4):635-8. 12. Allouche J, Bellon N, Saidani M, Stanchina-Chatrousse L, Masson Y, Patwardhan A, et al. In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells. Proc Natl Acad Sci USA 2015

Open access

Khair Fadel Merei Al Junidi, Mirjana Paravina, Vuka Katić and Pasxalina Mitsa

, Murphy GM, Hirose R, Chong AH. Skin disease in organ transplantation. Cambridge: Cambridge University Press; 2008. p. 137-41. 4. Owens DM, Wat FM. Contribution of stem cells and differentiated cells to epidermal tumours. Nat Rev Cancer 2003;3:444-51. 5. Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol 2009;60(6):1045-9. 6. Robinson JK, Dahiya M. Basal cell carcinoma with pulmonary and lymph node metastasis causing death. Arch Dermatol 2003;139:643. 7